Treatment of Nonalcoholic Fatty Liver Disease with Total Alkaloids in Rubus aleaefolius Poir through Regulation of Fat Metabolism

被引:10
|
作者
Li, Ying [1 ,2 ]
Zhao, Jinyan [3 ,4 ]
Zheng, Haiyin [5 ]
Zhong, Xiaoyong [3 ,4 ]
Zhou, Jianheng [5 ]
Hong, Zhenfeng [3 ,4 ]
机构
[1] Xiamen Hosp Tradit Chinese Med, Xiamen 361009, Fujian, Peoples R China
[2] Jinshan St Community Hlth Serv, Xiamen 361000, Fujian, Peoples R China
[3] Fujian Univ Tradit Chinese Med, Acad Integrat Med, Fuzhou 350122, Fujian, Peoples R China
[4] Fujian Univ Tradit Chinese Med, Fujian Key Lab Integrat Med Geriatr, Fuzhou 350122, Fujian, Peoples R China
[5] Dept Integrat Med, Fuzhou 350122, Fujian, Peoples R China
关键词
MALONYL-COA; INSULIN-RESISTANCE; HEPATIC STEATOSIS; RISK-FACTORS; STEATOHEPATITIS; PREVALENCE; KINASE; MICE;
D O I
10.1155/2014/768540
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Total alkaloids in Rubus aleaefolius Poir (TARAP) is a folk medicinal herb that has been used clinically in China to treat nonalcoholic fatty liver disease (NAFLD) for many years. However, the mechanism of its anti-NAFLD effect is largely unknown. In this study, we developed a NAFLD rat model by supplying a modified high-fat diet (mHFD) ad libitum for 8 weeks and evaluated the therapeutic effect of TARAP in NAFLD rats as well as the underlying molecular mechanism. We found that TARAP could reduce the serum triglycerides (TG), total cholesterol (TC), and low-density lipoprotein (LDL-C) levels and increase the serum high-density lipoprotein (HDL-C) level in NAFLD rats. In addition, TARAP treatment reduced expression of fatty acid synthetase (FAS), and acetyl-CoA carboxylase (ACC) and upregulated the expression of carnitine palmitoyltransferase (CPT). Our results suggest that regulation of lipid metabolism may be a mechanism by which TARAP treats NAFLD.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Treatment strategies in nonalcoholic fatty liver disease
    Tilg, H
    Kaser, A
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2005, 2 (03): : 148 - 155
  • [32] The Future of Nonalcoholic Fatty Liver Disease Treatment
    Mazhar, Khurram
    MEDICAL CLINICS OF NORTH AMERICA, 2019, 103 (01) : 57 - +
  • [33] Treatment strategies in nonalcoholic fatty liver disease
    Herbert Tilg
    Arthur Kaser
    Nature Clinical Practice Gastroenterology & Hepatology, 2005, 2 : 148 - 155
  • [34] Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease
    Aggeletopoulou, Ioanna
    Kalafateli, Maria
    Tsounis, Efthymios P.
    Triantos, Christos
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)
  • [35] Antioxidant treatment in nonalcoholic fatty liver disease
    Celikbilek, Mehmet
    Dogan, Serkan
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2014, 25 (04): : 468 - 468
  • [36] Which treatment for nonalcoholic fatty liver disease?
    Moscatiello, S.
    Marzocchi, R.
    Villanova, N.
    Bugianesi, E.
    Marchesini, G.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2008, 8 (08) : 767 - 775
  • [37] Prevention and treatment of nonalcoholic fatty liver disease
    Targher, Giovanni
    Bellis, Alessandro
    Fornengo, Paolo
    Ciaravella, Francesca
    Pichiri, Isabella
    Perin, Paolo Cavallo
    Trimarco, Bruno
    Marchesini, Giulio
    DIGESTIVE AND LIVER DISEASE, 2010, 42 (05) : 331 - 340
  • [38] Treatment of diabetes in nonalcoholic fatty liver disease
    Bodis, K.
    Roden, M.
    DIABETOLOGE, 2016, 12 (07): : 486 - 493
  • [39] Nonalcoholic Fatty Liver Disease and Obesity Treatment
    Katherine T. Brunner
    Cameron J. Henneberg
    Robert M. Wilechansky
    Michelle T. Long
    Current Obesity Reports, 2019, 8 : 220 - 228
  • [40] Update cognition of nonalcoholic fatty liver disease/metabolism-associated fatty liver disease
    Gu Weijun
    Mu Yiming
    慢性疾病与转化医学(英文), 2022, 08 (01) : 5 - 6